TLSI · TriSalus Life Sciences Inc
United States · RS rating 21 · As of 2026-11-03
| Price | 3.48 USD |
|---|---|
| 1-day change | -4.1% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 21 / 26 / 33 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 13 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +78.1% |
| Sales growth Q/Q | +14.2% |
| Distance from 52-week high | +53.6% |
| Market cap (USD) | $284.3M |